Research
Tributyrin
5 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
A retrospectively registered pilot randomized controlled trial of postbiotic administration during antibiotic treatment increases microbiome diversity and enriches health-associated taxa.
A single-center, randomized placebo-controlled trial involving 32 patients examined the effects of a fermentation-derived postbiotic administered alongside antibiotics and probiotics for non-GI infections. The postbiotic group showed significantly higher fecal bacterial alpha diversity and enrichment of health-associated taxa, suggesting postbiotic co-administration may mitigate antibiotic-induced microbiome injury.
Preliminary effect of the postbiotic pA1c®HI in glucose metabolism of obese individuals: A pilot, randomized, double-blind, controlled nutritional intervention.
A randomized, double-blind, placebo-controlled study assessed the impact of pA1c®HI postbiotic on glucose metabolism, weight management, and metabolic health in obese individuals. The study found improvements in glucose metabolism, body composition, and reductions in diastolic blood pressure with pA1c®HI supplementation compared to placebo.
Postbiotic Supplementation Increases Amino Acid Absorption from Plant-Based Meal: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study.
This placebo-controlled, randomized, double-blind, crossover study assessed the effects of postbiotic and probiotic supplementation on amino acid absorption from a plant-based meal in 16 male participants. Postbiotic supplementation significantly improved absorption profiles for various individual amino acids and total amino acids compared to placebo.
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.
This study evaluated the pharmacokinetics and clinical effects of tributyrin, an oral butyrate prodrug, in 20 patients with advanced solid tumors. Tributyrin was administered at doses from 150 to 200 mg/kg three times daily. The study found that tributyrin is well tolerated and achieves butyrate levels associated with in vitro activity, although no objective responses were observed.
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Phase I study of orally administered tributyrin in 13 patients with solid tumors, with doses ranging from 50 to 400 mg/kg/day. The study assessed the pharmacokinetics of butyrate in plasma and observed various toxicities. Peak plasma butyrate concentrations were achieved but disappeared by 5 hours post-dose.